Cargando…

Structural basis for inhibition of the AAA-ATPase Drg1 by diazaborine

The hexameric AAA-ATPase Drg1 is a key factor in eukaryotic ribosome biogenesis and initiates cytoplasmic maturation of the large ribosomal subunit by releasing the shuttling maturation factor Rlp24. Drg1 monomers contain two AAA-domains (D1 and D2) that act in a concerted manner. Rlp24 release is i...

Descripción completa

Detalles Bibliográficos
Autores principales: Prattes, Michael, Grishkovskaya, Irina, Hodirnau, Victor-Valentin, Rössler, Ingrid, Klein, Isabella, Hetzmannseder, Christina, Zisser, Gertrude, Gruber, Christian C., Gruber, Karl, Haselbach, David, Bergler, Helmut
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8190095/
https://www.ncbi.nlm.nih.gov/pubmed/34108481
http://dx.doi.org/10.1038/s41467-021-23854-x
Descripción
Sumario:The hexameric AAA-ATPase Drg1 is a key factor in eukaryotic ribosome biogenesis and initiates cytoplasmic maturation of the large ribosomal subunit by releasing the shuttling maturation factor Rlp24. Drg1 monomers contain two AAA-domains (D1 and D2) that act in a concerted manner. Rlp24 release is inhibited by the drug diazaborine which blocks ATP hydrolysis in D2. The mode of inhibition was unknown. Here we show the first cryo-EM structure of Drg1 revealing the inhibitory mechanism. Diazaborine forms a covalent bond to the 2′-OH of the nucleotide in D2, explaining its specificity for this site. As a consequence, the D2 domain is locked in a rigid, inactive state, stalling the whole Drg1 hexamer. Resistance mechanisms identified include abolished drug binding and altered positioning of the nucleotide. Our results suggest nucleotide-modifying compounds as potential novel inhibitors for AAA-ATPases.